IMbrave050 Study: A Revolutionary Breakthrough in Hepatocellular Carcinoma Adjuvant Therapy
-
Published:2024-05
Issue:3
Volume:14
Page:101360
-
ISSN:0973-6883
-
Container-title:Journal of Clinical and Experimental Hepatology
-
language:en
-
Short-container-title:Journal of Clinical and Experimental Hepatology
Reference12 articles.
1. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial;Qin;Lancet Lond Engl,2023
2. 2023 update of Indian national association for study of the liver consensus on management of intermediate and advanced hepatocellular carcinoma: the Puri III recommendations;Kumar;J Clin Exp Hepatol,2024
3. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020
4. 2019 update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the Puri II recommendations;Kumar;J Clin Exp Hepatol,2020
5. Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer criteria;Tsilimigras;Ann Surg Oncol,2020